Joseph A. Prezioso
University of Pittsburgh
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joseph A. Prezioso.
International Journal of Cancer | 2004
Yezhou Sheng; Jianyi Hua; Kevin G. Pinney; Charles M. Garner; Robert R. Kane; Joseph A. Prezioso; David J. Chaplin; Klaus Edvardsen
The mechanism of tumor cell killing by OXI4503 was investigated by studying vascular functional and morphological changes post drug administration. SCID mice bearing MHEC5‐T hemangioendothelioma were given a single dose of OXI4503 at 100 mg/kg. Tumor blood flow, measured by microsphere fluorescence, was reduced by 50% at 1 hr, and reached a maximum level 6–24 hr post drug treatment. Tumor vascular permeability, measured by Evans blue and hemoglobin, increased significantly from 3 hr and peaked at 18 hr. The elevated tumor vessel permeability was accompanied by an increase in vascular endothelial growth factor (VEGF) from 1 hr post drug treatment. Immunohistochemical staining for CD31 and laminin showed that tumor blood vessels were affected as early as 3 hr but more prominent from 6 hr. From 12 hr, the vessel structure was completely destroyed. Histopathological and double immunohistochemical staining showed morphological change and induction of apoptosis in endothelial cells at 1–3 hr, followed by tumor cell necrosis from 6–72 hr. There were no statistically significant changes of Evans blue and hemoglobin contents in liver tissue over the time course. These results suggest that OXI4503 selectively targets tumor blood vessels, and induces blood flow shutdown while it enhances tumor blood vessel permeability. The early induction of endothelial cell apoptosis leads to functional changes of tumor blood vessels and finally to the collapse of tumor vasculature, resulting in massive tumor cell necrosis. The time course of the tumor vascular response observed with OXI4503 treatment supports this drug for development as a stand alone therapy, and also lends support for the use of the drug in combination with other cancer therapies.
Cancer Letters | 1992
Joseph A. Prezioso; Michael W. Epperly; Nu Wang; William D. Bloomer
The rationale for melanoma specific antitumor agents containing phenolic amines is based in part upon the ability of the enzyme tyrosinase to oxidize these prodrugs to toxic intermediates. Two phenolic amine compounds, N-acetyl-4-S-cysteaminylphenol (N-Ac-4-S-CAP) and 4-S-cysteaminylphenol (4-S-CAP), demonstrated growth inhibitory activity with a variety of melanoma cell lines and were essentially non-toxic to non-melanoma cell lines. Theophylline, an inhibitor of cyclic nucleotide phosphodiesterase, increased in situ tyrosinase activity and enhanced the antimelanoma effects of 4-S-CAP and N-Ac-4-S-CAP in pigmented melanoma cell lines. Phenylthiourea, a specific inhibitor of tyrosinase activity, partially blocked the growth inhibitory activity of N-Ac-4-S-CAP in human pigmented melanoma cells. Buthionine sulfoximine, an inhibitor of the synthesis of the cellular antioxidant glutathione, potentiated the growth inhibitory activity of N-Ac-4-S-CAP in pigmented melanoma cells.
Clinical & Experimental Metastasis | 1993
Joseph A. Prezioso; Nu Wang; Lisa Duty; William D. Bloomer; Elieser Gorelik
B16 melanoma sublines (B16-F10-BL6 and B16-Fl) exhibited elevated adenosine 3′,5′-cyclic monophosphate (cAMP) levels when cultured in Dulbeccos modified Eagles medium (DMEM) in comparison to cells in RPMI-1640 medium. In parallel, cells cultured in DMEM had increased tyrosinase activity, melanization and dendrite formation, all markers of melanoma differentiation. Also, the proliferative rates of both cell lines were decreased by 80–85% when cultured in DMEM relative to cells maintained in RPMI-1640 medium. In these studies, elevated levels of the melanin precursors tyrosine (Tyr) and phenylalanine (Phe) found in DMEM were shown not to be solely responsible for the phenotypic changes observed with DMEM. Both BL6 and B16-Fl cell lines formed more experimental pulmonary tumor metastasis in syngeneic C57BL/6 mice when maintained in DMEM vs RPMI-1640 medium. Analysis of metastasis formation in nude mice with normal and depleted natural killer (NK) cell activity revealed that the enhanced lung colonizing capacity of the BL6 cells maintained in DMEM was independent of the function of T-cell or NK-cell-mediated immunity. A close association between metastatic ability of tested lines and the expression of the membrane-associated enzyme γ-glutamyltranspeptidase (γ-GTPase, EC 2.3.2.2) was observed. The highly metastatic BL6 cell line had 20-fold higher levels of γ-GTPase activity than the weakly metastatic B16-Fl cell line. Both cell lines, when grown in DMEM, had elevated γ-GTPase activity that paralleled augmentation of metastatic ability. The dramatic changes in lung-colonizing capacity of the variant B16 melanoma cells maintained in DMEM in contrast to those grown in RPMI-1640 medium may serve as a useful model in understanding certain steps involved in triggering cell differentiation as well as metastasis development.
International Journal of Radiation Oncology Biology Physics | 1994
Joseph A. Prezioso; Donna Shields; Nu Wang; Maury Rosenstein
PURPOSE To elucidate the role of gamma-glutamyltranspeptidase-mediated glutathione transport on the radiosensitivity of B16 melanoma variant cell lines. METHODS AND MATERIALS B16 melanoma variant cell lines were examined for their levels of gamma-glutamyltranspeptidase (GGTP; E.C. 2.3.2.2), a plasma membrane-associated ectoenzyme that is involved in the transport of extracellular glutathione, by flow cytometric and biochemical analysis. B16 cell lines were examined for rates of de novo glutathione synthesis from extracellular glutathione and for their sensitivity to gamma-irradiation and glutathione synthesis inhibition. The GGTP inhibitors were examined for their effect on the radiosensitivity of B16 melanoma cells. RESULTS B16-F10-BL6 (BL6) melanoma cells were shown to express a 20-fold higher level of GGTP than the B16-F1 melanoma variant cells. Cultures of BL6 and B16-F1 cells depleted extracellular glutathione at rates of 2.4 and < 0.1 nmol glutathione/10(6) cells/h, respectively, and BL6 cells exported glutathione at a rate 7.2-fold higher than B16-F1 cells (710 and 98 pmol glutathione/10(6) cells/h, respectively). BL6 melanoma cells replenished exhausted intracellular glutathione levels from an extracellular glutathione source at a rate of 1.21 nmol glutathione/h (18% basal glutathione/h); however, B16-F1 cells lacked the capacity to replenish intracellular glutathione despite the presence of exogenous glutathione in the culture medium. BL6 melanoma cells were radioresistant compared to the B16-F1 cell line, exhibiting extrapolation numbers (ñ) of 14.9 and 1.0, respectively, and a lower surviving fraction to a wide range of radiation doses. The GGTP inhibitor combination of L-serine and sodium borate blocked the repletion of intracellular glutathione and in the presence or absence of buthionine sulfoximine-mediated depletion of glutathione reverses the radiation resistance in BL6 melanoma cells to near baseline levels observed with the B16-F1 parent clone. Serine-borate treatment of low-GGTP expressing B16-F1 cells had no effect on the ñ value or the surviving fraction of cells to a range of ionizing irradiation doses. CONCLUSIONS These results suggest that GGTP plays an important role in the extracellular metabolism and transport of glutathione, which also provides radioresistance to BL6 melanoma cells in vitro.
Cancer Chemotherapy and Pharmacology | 1992
Joseph A. Prezioso; Nu Wang; William D. Bloomer
SummaryThe rationale for melanoma-specific antitumor agents containing phenolic amines is based in part on the ability of the enzyme tyrosinase to oxidize these prodrugs to toxic intermediates. The phenolic amine compounds 4-S-cysteaminylphenol (4-S-CAP) andN-acetyl-4-S-cysteaminylphenol (N-Ac-4-S-CAP) inhibited in situ thymidylate synthase activity in pigmented melanoma cell lines but had little or no effect on nonpigmented and nonmelanoma cell lines. Theophylline, a cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitor, increased tyrosinase activity and potentiated the inhibition of in situ thymidylate synthase by N-Ac-4-S-CAP. The inhibition of in situ thymidylate synthase by both drugs in pigmented melanoma cells correlated with the inhibition of DNA synthesis and cell growth and was not due to an indirect effect caused by inhibition of the enzyme dihydrofolate reductase. 4-S-CAP inhibition of thymidylate synthase activity in cell free extracts required oxidation of the drug. In the presence of tyrosinase, the concentration causing a 50% inhibition of thymidylate synthase activity (IC50) in cell-free extacts was <10 μM, but no inhibition was observed in its absence, even at a drug concentration of 500 μM. Two reducing agents, dithioerythritol and glutathione, effectively blocked the inhibition of thymidylate synthase by oxidized 4-S-CAP. In pigmented melanoma cells containing the enzyme tyrosinase, the quinone-mediated mechanism of inhibition of DNA synthesis via inhibition of thymidylate synthase may be uniquely important in the expression of phenolic amine cytotoxicity.
Biochemical Pharmacology | 1993
Joseph A. Prezioso; Kalyani M. Damodaran; Wang Nu; William D. Bloomer
A proposed mechanism for the melanoma specific activity of phenolic amines is based upon the ability of the enzyme tyrosinase to oxidize these prodrugs to toxic intermediates. In this study, we synthesized an iodinated analog of gamma-L-glutaminyl-4-hydroxybenzene (GHB) with increased antimelanoma activity in both human and murine melanoma cell lines. GHB and gamma-L-glutaminyl-4-hydroxy-3-iodobenzene (I-GHB) were shown to be substrates for both mammalian and mushroom tyrosinase. Glutathione, a cellular antioxidant, inhibited tyrosinase mediated formation of gamma-L-glutaminyl-3,4-benzoquinone (GBQ) from GHB, inhibited melanin production, and blocked the inhibition of the enzyme thymidylate synthase by oxidized GHB. Buthionine sulfoximine (BSO) depletion of cellular glutathione enhanced the growth inhibitory activity and the inhibition of in situ thymidylate synthase by phenolic amines in melanoma cells. GHB and I-GHB were shown to be approximately 5- and 10-fold more cytotoxic, respectively, in highly metastatic B16-BL6 cells than in weakly metastatic B16-F1 cells with approximately equal tyrosinase activity. B16-BL6 cells had approximately 20-fold higher gamma-glutamyltranspeptidase (gamma-GTPase) activity than B16-F1 cells which suggested the possible involvement of this enzyme in the activation of the cytotoxicity of the phenolic amines. 4-Aminophenol, a product of gamma-GTPase reaction with GHB, was a substrate for tyrosinase and a potent inhibitor of in situ thymidylate synthase activity in melanogenic cells. In pigmented melanoma cells containing the enzyme tyrosinase, the quinone mediated mechanism of phenolic amine cytotoxicity may be uniquely important and the cellular antioxidant glutathione essential in the detoxification of these quinone-generated intermediates.
Anticancer Research | 2003
Jianyi Hua; Yezhou Sheng; Kevin G. Pinney; Charles M. Garner; Robert R. Kane; Joseph A. Prezioso; George R. Pettit; David J. Chaplin; Klaus Edvardsen
Archive | 2002
David J. Chaplin; Charles M. Garner; Robert R. Kane; Kevin G. Pinney; Joseph A. Prezioso; Klaus Edvardsen
International Journal of Cancer | 1994
Joseph A. Prezioso; Rebecca P. Hughey; Nu Wang; Kalyani M. Damodaran; William D. Bloomer
Cytokine | 1995
Joseph A. Prezioso; Jue Wang; Misson Kim; Lisa Duty; David J. Tweardy; Elieser Gorelik